Veru (VERU) Set to Announce Quarterly Earnings on Thursday

Posted by on Aug 8th, 2023

Veru (NASDAQ:VERU – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, August 10th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Veru (NASDAQ:VERU – Get Free Report) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.11). Veru had a negative return on equity of 206.09% and a negative net margin of 652.36%. The business had revenue of $6.59 million for the quarter, compared to analysts’ expectations of $3.97 million. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru Stock Down 1.7 %

Shares of VERU stock opened at $1.13 on Tuesday. The firm has a market cap of $100.84 million, a P/E ratio of -0.65 and a beta of -0.14. The business has a 50-day moving average price of $1.19 and a two-hundred day moving average price of $2.11. Veru has a 12-month low of $0.93 and a 12-month high of $24.55.

Institutional Trading of Veru

Institutional investors have recently modified their holdings of the company. Swiss National Bank increased its holdings in Veru by 7.2% during the 1st quarter. Swiss National Bank now owns 151,000 shares of the company’s stock valued at $729,000 after purchasing an additional 10,100 shares during the period. Raymond James & Associates raised its holdings in shares of Veru by 4.9% during the first quarter. Raymond James & Associates now owns 85,100 shares of the company’s stock valued at $411,000 after acquiring an additional 4,000 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Veru by 2.9% during the first quarter. Bank of New York Mellon Corp now owns 215,790 shares of the company’s stock valued at $1,042,000 after acquiring an additional 6,161 shares in the last quarter. Rhumbline Advisers lifted its stake in Veru by 3.6% in the first quarter. Rhumbline Advisers now owns 68,654 shares of the company’s stock worth $332,000 after acquiring an additional 2,410 shares during the period. Finally, Blair William & Co. IL raised its holdings in Veru by 4.8% in the 1st quarter. Blair William & Co. IL now owns 329,925 shares of the company’s stock worth $1,594,000 after purchasing an additional 15,000 shares in the last quarter. 41.40% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VERU has been the topic of a number of recent research reports. Jefferies Financial Group raised Veru from an “underperform” rating to a “hold” rating in a research note on Wednesday, June 7th. HC Wainwright decreased their price target on Veru from $6.00 to $2.00 in a research note on Monday, May 15th.

Check Out Our Latest Research Report on VERU

About Veru

(Get Free Report)

Veru Inc, a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms.

Featured Articles

Earnings History for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.